CA2327398A1 - Methods and compositions for stabilizing acetylcholine compositions - Google Patents

Methods and compositions for stabilizing acetylcholine compositions Download PDF

Info

Publication number
CA2327398A1
CA2327398A1 CA002327398A CA2327398A CA2327398A1 CA 2327398 A1 CA2327398 A1 CA 2327398A1 CA 002327398 A CA002327398 A CA 002327398A CA 2327398 A CA2327398 A CA 2327398A CA 2327398 A1 CA2327398 A1 CA 2327398A1
Authority
CA
Canada
Prior art keywords
acetylcholine
compositions
buffered
stabilizing
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002327398A
Other languages
French (fr)
Other versions
CA2327398C (en
Inventor
Fu-Pao Tsao
George Edward Minno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2327398A1 publication Critical patent/CA2327398A1/en
Application granted granted Critical
Publication of CA2327398C publication Critical patent/CA2327398C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymerisation Methods In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A pharmaceutical product which includes two-chambers, one having a buffered diluent and the other having acetylcholine. Upon mixing the chamber contents, a buffered efficacious acetylcholine product is prepared for post-surgical ophthalmic injection. Another embodiment of the invention is a method of providing an acetylcholine product which has a substantially consistent final pH without substantial degradation of the acetylcholine. The method involves storing an unbuffered acetylcholine separate from a diluent solution which has been buffered, and mixing prior to use.
CA002327398A 1998-04-29 1999-04-27 Methods and compositions for stabilizing acetylcholine compositions Expired - Fee Related CA2327398C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6955298A 1998-04-29 1998-04-29
US09/069,552 1998-04-29
PCT/EP1999/002846 WO1999055304A1 (en) 1998-04-29 1999-04-27 Methods and compositions for stabilizing acetylcholine compositions

Publications (2)

Publication Number Publication Date
CA2327398A1 true CA2327398A1 (en) 1999-11-04
CA2327398C CA2327398C (en) 2008-12-30

Family

ID=22089751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002327398A Expired - Fee Related CA2327398C (en) 1998-04-29 1999-04-27 Methods and compositions for stabilizing acetylcholine compositions

Country Status (25)

Country Link
US (1) US6261546B1 (en)
EP (1) EP1073413B1 (en)
JP (1) JP2002512945A (en)
KR (1) KR100617429B1 (en)
CN (1) CN1147289C (en)
AT (1) ATE286380T1 (en)
AU (1) AU745124B2 (en)
BR (1) BR9910077A (en)
CA (1) CA2327398C (en)
CZ (1) CZ301969B6 (en)
DE (1) DE69923063T2 (en)
EE (1) EE04515B1 (en)
ES (1) ES2235486T3 (en)
HK (1) HK1034204A1 (en)
HU (1) HU226104B1 (en)
ID (1) ID26032A (en)
IL (1) IL138775A0 (en)
NO (1) NO20005372L (en)
NZ (1) NZ507074A (en)
PL (1) PL194092B1 (en)
PT (1) PT1073413E (en)
RU (1) RU2225199C2 (en)
SI (1) SI1073413T1 (en)
UA (1) UA72209C2 (en)
WO (1) WO1999055304A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529425T1 (en) 2006-11-30 2011-11-15 Nihon Mediphysics Co Ltd COMPOUNDS WITH AFFINITY TO AMYLOID
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009892A (en) * 1989-03-03 1991-04-23 Mckinzie James W Rapid miosis with control of intraocular pressure
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber

Also Published As

Publication number Publication date
EE200000625A (en) 2002-02-15
HUP0100613A2 (en) 2001-08-28
ID26032A (en) 2000-11-16
DE69923063T2 (en) 2005-12-22
IL138775A0 (en) 2001-10-31
UA72209C2 (en) 2005-02-15
US6261546B1 (en) 2001-07-17
CN1147289C (en) 2004-04-28
CZ301969B6 (en) 2010-08-18
DE69923063D1 (en) 2005-02-10
CA2327398C (en) 2008-12-30
EP1073413A1 (en) 2001-02-07
SI1073413T1 (en) 2005-08-31
ATE286380T1 (en) 2005-01-15
WO1999055304A1 (en) 1999-11-04
CZ20003961A3 (en) 2001-01-17
EE04515B1 (en) 2005-08-15
JP2002512945A (en) 2002-05-08
AU4034099A (en) 1999-11-16
HUP0100613A3 (en) 2001-12-28
KR20010043121A (en) 2001-05-25
HU226104B1 (en) 2008-04-28
PL343174A1 (en) 2001-07-30
PT1073413E (en) 2005-04-29
RU2225199C2 (en) 2004-03-10
BR9910077A (en) 2000-12-26
HK1034204A1 (en) 2001-10-19
NO20005372D0 (en) 2000-10-25
CN1298295A (en) 2001-06-06
NZ507074A (en) 2004-02-27
EP1073413B1 (en) 2005-01-05
NO20005372L (en) 2000-10-25
PL194092B1 (en) 2007-04-30
AU745124B2 (en) 2002-03-14
KR100617429B1 (en) 2006-08-30
ES2235486T3 (en) 2005-07-01

Similar Documents

Publication Publication Date Title
CA2216535A1 (en) Protein kinase c inhibitors
CA2137203A1 (en) Protein kinase c inhibitors
CA2094483A1 (en) Cosmetic composition and process for making it
IE43579L (en) Heteroaryl compounds
CA2200195A1 (en) Use of aromatase inhibitors for the production of a pharmaceutical agentfor treating a relative androgen deficiency in men
IE890357L (en) Method for Preventing Secondary Effects
CA2170622A1 (en) Oral Formulations of an Antifungal
CA2416403A1 (en) A medicinal aerosol formulation
ZA973647B (en) Inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them.
AU7640696A (en) Thiazolidinedione derivatives, method for preparing the derivatives and pharmaceutical compositions containing same
CA2192418A1 (en) New crystal modification of cdch, a process for its preparation and pharmaceutical formulations comprising this modification
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
TR27271A (en) N-substituted pyrazole derivatives, processes for their preparation, compositions containing them and their use as herbicides.
CA2264063A1 (en) Cryptophycin compounds
CA2376894A1 (en) Pharmaceutical composition comprising a protein and an ectoine
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
HUP9802492A3 (en) Benzisoxazole and indazole derivatives as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same
CA2327398A1 (en) Methods and compositions for stabilizing acetylcholine compositions
AU1869601A (en) Pharmaceutical compositions comprising trimegestone
DK0830132T3 (en) Pharmaceutical formulation containing thiagabine hydrochloride as well as the process for its preparation
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
AU6975591A (en) Pharmaceutical composition for treating or preventing retroviral infections
WO2002022106A3 (en) Stable ophthalmic preparation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed